Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Shares Issued (2020 - 2025)

Historic Shares Issued for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $49000.0.

  • Foghorn Therapeutics' Shares Issued changed N/A to $49000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $442000.0, marking a year-over-year decrease of 9957.33%. This contributed to the annual value of $103.4 million for FY2024, which is 571557.93% up from last year.
  • Foghorn Therapeutics' Shares Issued amounted to $49000.0 in Q3 2025.
  • In the past 5 years, Foghorn Therapeutics' Shares Issued ranged from a high of $102.2 million in Q2 2024 and a low of $16000.0 during Q4 2022
  • Over the past 5 years, Foghorn Therapeutics' median Shares Issued value was $254000.0 (recorded in 2025), while the average stood at $8.8 million.
  • As far as peak fluctuations go, Foghorn Therapeutics' Shares Issued crashed by 9996.15% in 2022, and later surged by 9915631.07% in 2024.
  • Over the past 5 years, Foghorn Therapeutics' Shares Issued (Quarter) stood at $41.5 million in 2021, then plummeted by 99.96% to $16000.0 in 2022, then skyrocketed by 1062.5% to $186000.0 in 2023, then soared by 54864.52% to $102.2 million in 2024, then plummeted by 99.95% to $49000.0 in 2025.
  • Its Shares Issued stands at $49000.0 for Q3 2025, versus $254000.0 for Q2 2025 and $139000.0 for Q1 2025.